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Abstract
Background: Lack of folic acid intake or genetic abnormalities in folic acid metabolism was correlates with elevated
plasma or serum homocysteine concentrations. This case-control analytical study aims to determine the correlation
between folic acid and homocysteine levels in severe pre-eclampsia and normal pregnancy. Methods: We enrolled 46
pregnant women (age 20─35 years) with severe pre-eclampsia or normal pregnancy at a government hospital in Padang,
Indonesia, between March and May 2015. The samples size was selected by consecutive sampling. Then, we determined
folic acid and homocysteine levels using ELISA and statistical analysis using the independent t-test and Pearson
correlation. Results: We observed a difference in folic acid levels between severe pre-eclampsia (39.48 ± 9.40 ng/mL)
and normal pregnancy (47.04 ± 13.20 ng/mL, p < 0.05). A difference was also observed in homocysteine levels between
pre-eclampsia (18.52 ± 0.41 pmol/mL) and normal pregnancy (17.80 ± 0.73 pmol/mL, p < 0.05). The correlation between
folic acid and homocysteine in severe pre-eclampsia and normal pregnancy was negative (r = -0.034, and r = -0.222,
p > 0.05, respectively). Conclusions: Low folic acid levels tend to increase homocysteine levels in severe preeclampsia, whereas high folic acid levels tend to lower homocysteine levels in normal pregnancy.
Keywords: folic acid, homocysteine, pre-eclampsia, pregnancy

Hyperhomocysteinemia causes endothelial dysfunction
through several direct toxic mechanisms and oxidative
stress.8,9 In addition, hyperhomocysteinemia decreases
the bioactivity of nitric oxide (NO), a relaxing smooth
muscle factor that is a vasodilator and lubricant to prevent
the attachment of low-density lipoprotein and blood cells,
as well as in response to various stimuli.6 Moreover, NO
induces vasodilation and regulates vascular resistance.
The NO reduction causes endothelial dysfunction
Reportedly, the disruption of endothelial function as a
vasodilator plays a role in the pathophysiology of
hypertension.8

Introduction
To date the cause of pre-eclampsia remains unclear.
However, endothelial cell activation has been the centre
of contemporary understanding of the pathogenesis of
pre-eclampsia over the past two decades.1 Healthy endothelial cells can maintain vascular integrity, preventing
platelet adhesion and affecting the vascular smooth
muscle tone. The presence of endothelial damage results
in an inability to maintain the function resulting in the
increased vascular permeability, platelet thrombosis,
and increased vascular tone.1 Vascular damage to poor
maternal uteroplacental circulation and foetal umbilical
accounts for pre-eclampsia. Reportedly, one of the factors
causing vascular damage to pre-eclampsia is
homocysteine.2 In facts, several have reported that
homocysteine is elevated in women with severe preeclampsia.3-5

Primarily, homocysteine metabolism depends on three
enzymes (methionine synthase, 5,10-methylenetetrahydrofolate reductase-, and cystathionine β- synthase
(CBS) and some cofactor vitamins (B6, B12-, and folic
acid). Both folic acid and vitamin B play a vital role in
various biochemical processes, including homocysteine
metabolism.9 In fact folic essential in two biochemical
cycles involved in the biosynthesis of the deoxyribonucleic acid (DNA) and one-carbon metabolism
(DNA, lipid and protein methylation). In addition, folic
acid is a major substrate for the conversion of
homocysteine to methionine.6 Studies have established

Homocysteine is a non-proteinogenic -amino acid and
an intermediate compound produced in the methionine
metabolism. Methionine is an essential amino acid
containing sulphur obtained from the intake of proteinrich food.6 Reportedly, elevated total plasma homocysteine levels are a risk factor for vascular disease.7
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that a lack of folic acid intake or genetic abnormalities
in folic acid metabolism is correlates with elevated
plasma or serum homocysteine concentrations.3,6,10–12
Furthermore, low folate levels have been detected in
patients with pre-eclampsia.13 A correlation between
folate deficiency and an increase in total homocysteine
(tHcy) has been extensively reported.2,14–16 However,
some studies have reported no correlation between folic
acid and homocysteine levels.3,8,12,17 The controversy
surrounding the role of folic acid in increasing
homocysteine levels prompted the researchers to seek
further clarification. Hence, this study aims to determine
the correlation between folic acid level and plasma
homocysteine in pre-eclampsia and normal pregnancy.

Methods
Study design and study cohort. This case-control
analytical study was conducted at a government hospital
in Padang, Indonesia, from March to May 2015. We
enrolled all normal pregnant women with 37–40 weeks
gestation and severe pre-eclampsia with 20–40 weeks
gestation. The study cohort comprised pregnant women
with severe pre-eclampsia or those with normal pregnancy
who fulfilled the inclusion and exclusion criteria. Severe
pre-eclampsia was a condition of hypertension in a
pregnancy diagnosed after 20 weeks' gestation with a
blood pressure ≥ 160/110 mmHg and accompanied by
proteinuria ≥ +1 with dipstick examination. The inclusion
criteria were as follows: single and double pregnancy,
nulliparity and multiparity and age 20–35 years. Conversely, the exclusion criteria were as follows: patients
undergoing treatment that affected homocysteine levels
(epilepsy, cancer and asthma), patients consuming beer or
the like containing 1 cup alcohol/day, drinking >5 cups
of coffee/day and smoking >1 cigarette/day; hystory of
heart disease, kidney disease, hypertension, diabetes
mellitus, asthma and epilepsy based on anamnesis and
medical record.
This study protocol received ethical approval from
Research Ethics Committee of Faculty of Medicine
Andalas University, Padang (No. 024/KEP/FK/2015).
Participants were given an explanation before approval
and then signed an informed concent. The sample size
was determined based on the formula for calculating the
sample size using two independent populations18 as 46
(each group included 23 individuals). Sampling was
performed using consecutive sampling technique.
Data collection. We assessed folic acid and homocysteine levels using spectrophotometer with the ELISA
method, conducted at Biomedical Laboratory Faculty of
Medicine Andalas University. Using the Human VB9/
Folic Acid ELISA kit (Elabscience), we detected folic
acid levels (0–200 ng/mL). In addition, we used the
Human Homocysteine ELISA Kit (Elabscience) to
detect homocysteine levels (0–60 pmol/mL). From all
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participants, we obtained 3 cm3 of venous blood plasma
from the antecubital vein area in the supine position.
Then, within 30 min of drawing blood, the blood sample
was stored in an EDTA-containing tube, carefully shaken
and centrifuged at 1000 g for 15 min at 2 °C–8 C.
Next, we removed the centrifuged plasma into the sample
cup. Finally, the blood samples were sent to the Biomedical Laboratory of the Faculty of Medicine Andalas
University and stored at –80 C until examination.
Statistical analysis. Samples were first analysed in the
laboratory and then processing and analyzing data used
IBM SPSS Statistics Version 20, with 95% confidence
intervals (α = 0.05; β = 80%). P value was used to analyse
significance criteria; if p ≤ 0.05 means significant.
Normality test was analysed by One-Sample Kolmogorov
Smirnov. The numerical data with normal distribution
was calculated on mean and standard deviations. The
categorical data were calculated in frequency and analysed
by Chi-square The difference between folic acid and
homocysteine was analysed by independent t-test. Pearson
correlation test was used to analyse correlation between
folic acid and homocysteine.

Results
We examined 46 pregnant women in this study. In the
severe pre-eclampsia group, the mean age of pregnant
women (29.65  4.30 years) tended to be older than that
in the normal pregnancy group (28.83  3.60 years); we
observed no difference between the two groups (p =
0.484). The mean gestational age in the severe preeclampsia group (35.17  3.48 weeks) was shorter
compared with the normal pregnancy group (38.30 
1.14 weeks); we observed a marginal difference between
severe pre-eclampsia and normal pregnancy (p = 0,000).
The mean body mass index before pregnancy in the
severe pre-eclampsia group (22.60  4.32 kg/m2) was
lower than normal pregnancy (23.40  5.09 kg/m2); no
difference was observed between the two groups (p =
0.564). Based on parity, we determined that eight
women (34.8%) had severe pre-eclampsia, whereas,
amongst multiparas, 15 women (65.2%) had severe preeclampsia: we observed no assosiation parity with severe
pre-eclampsia (p = 0.75). Based on the history of preeclampsia, three women (20%) having mothers with a
history of pre-eclampsia had severe pre-eclampsia in
this pregnancy; no association PE history with severe
pre-eclampsia; p = 0.18 (Table 1).
The mean folic acid levels of severe pre-eclampsia
(39.48 ± 9.40 ng/mL) tended to be lower than that in
normal pregnancy group (47.04 ± 13.20 ng/mL); we
observed difference between severe pre-eclampsia and
normal pregnancy (p = 0.031; p < 0.05). The mean
homocysteine levels of severe pre-eclampsia (18.52 ± 0.41
August 2018 | Vol. 22 | No. 2
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Table 1. Characteristics of the Study Cohort
Variable
Age of mother (year)
Duration of pregnancy (weeks)
BMI before pregnancy (kg/m2)

Severe pre-eclampsia (n = 23)
(mean  SD)
29.65  4.30
35.17  3.48
22.60  4.32

Normal pregnancy (n = 23)
(mean  SD)
28.83  3.60
38.30  1.14
23.40  5.09

p
0.484#
0.000#**
0.564#

Parity
- Nulliparity
- Multiparity

8 (34.8)
15 (65.2)

6 (26.1)
17 (73.9)

0.75*

PE History
- Yes
- No

3 (20%)
12 (80%)

0 (0%)
17 (100%)

0.18*

39.48  9.40
18.52  0.41

47.04  13.20
17.80  0.73

Folic acid (ng/mL)
Homocysteine levels (pmol/mL)
#independent t-test *p < 0.05
*Chi-square test

0.031#**
0.000#**

In the severe pre-eclampsia group, the correlation was
insignificant between folic acid and homocysteine (r = –
0.034; R2 = 0.001; p = 0.879; Figure 1). In addition, the
correlation between folic acid and homocysteine in
normal pregnancy was r = –0.222 (R2 = 0.049),
suggesting insignificant negative correlation between
folic acid and homocysteine in normal pregnancy (p =
0.308; Figure 2).

Discussion

Figure 1. Correlation Between Folic Acid Level and
Homocysteine in Severe Pre-Eclampsia

Figure 2.

Correlation Between Folic Acid Level and
Homocysteine in Normal Pregnancy

pmol/mL) tended to be higher than that in normal
pregnancy (17.80 ± 0.73 pmol/mL); we observed marginal
difference between the two groups (p = 0,000).
Makara J. Health Res.

Correlation between folic acid levels and homocysteine
in pre-eclampsia. Hyperhomocysteinemia is one of the
leading factors that causes vascular damage to preeclampsia.2 Most studies have reported that homocysteine
levels are elevated in women with severe pre-eclampsia.3–5
Homocysteine causes oxidative stress accounting for
endothelial cell damage that plays a role in the pathophysiology of pre-eclampsia. Homocysteine can cause
direct vascular damage and may increase the reactive
oxygen species (ROS) production in endothelial and
smooth muscle cells.11 In vitro studies have reported
homocysteine to cause endothelial cell changes. Reportedly, elevated homocysteine levels alter the function
of the vascular endothelial cell surface from anticoagulant
to pro-coagulant and smooth muscle cell proliferation.19
Homocysteine rapidly reacts with NO to form S-nitrosoHcy, which acts as a potent antiplatelet agent and
vasodilator; this formation might decline the peroxide
production from homocysteine.19 Vascular injury is
attributed to an imbalance of the NO production of
dysfunctional endothelial cells and homocysteine
concentrations. In addition, homocysteine reduces the
expression of antioxidant enzyme glutathione peroxidase
and enhances the natural killer factor B.11
Homocysteine reduces cell viability in a time and
concentration dependent manner.19 In a study, the
August 2018 | Vol. 22 | No. 2
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highest cytotoxicity was reported by 80-M homocysteine
resulting in 80% of cell death after 5 days. Furthermore,
the study reported a marked decline in the cell viability of
35% after 5-day incubation with 40-M homocysteine.19
One of the functions of vitamins is enzyme cofactors.
Vitamin B6, B12 and folic acid are vital cofactors for
the methionine–homocysteine metabolism. Thus, low
availability of vitamin B (B6, B12 and folic acid) prevents
remethylation of homocysteine into methionine, thereby
accumulating homocysteine.19 Vitamin B decreases homocysteine without improving endothelial dysfunction or
hypercoagulability. Recent findings have suggested that
homocysteine accumulates secondary to immune activation–related increased oxidative stress. The correlation
between cardiovascular disease and homocysteine could
stem from vitamin B deficiency or only the reactivity of
vascular changes when folate levels are low simultaneously.19 Furthermore, some vitamin therapies
prevent vascular complications of homocystinuria, and
vitamin use is related to a lower risk of vascular disease
in the general population.20,21 However, Previous studies
reported a correlation between low plasma folate levels
and high homocysteine concentrations in preeclampsia.2,16,22,23 Folate acts as a precursor for 5methyltetrahydrofolate, methyl donor for Hcy
remethylation to methionine,24 thus, Hcy auto-oxidation
produces oxidised disulphide, two protons (H+) and two
electrons (e–) that stimulate the formation of the ROS
does not occur.24,25
In this study, the absence of a correlation between folic
acid levels and homocysteine attributed to higher folic
acid levels than normal. High folate intake or
supplementation before 20 weeks of pregnancy assumed
to play a role in decreasing homocysteine levels. In
addition, this study establishes that folic acid may not be
a major predictor of elevated homocysteine levels in
pre-eclampsia. There is still much more to be learnt
about the relationship between pre-eclampsia and
hyperhomocysteinemia. Notably, trans-sulphuration
insufficiency (via the CBS mutation or vitamin B6
deficiency) or restriction on remethylation (vitamin B12
deficiency or polymorphic genetic disorder methylenetetrahydrofolate reductase/MTHFR C677T) results in
homocysteine accumulation.25 Reportedly, the thermoplastic MTHFR C677T polymorphic gene reduces 50%
enzymatic activity in patients with folate deficiency.25
Correlation between folic acid levels and homocysteine
in normal pregnancy. In this study, high folic acid
levels in normal pregnant women inversely correlated
with low homocysteine levels or tended to exhibit lower
homocysteine levels. High folate levels could be
attributed to folate supplementation during pregnancy
obtained during pregnancy screening visits. In addition,
it is influenced by folate levels in previous pregnancies
that have reached the normal limit or parity distance of
Makara J. Health Res.

>2 years so that mothers already have high folate
reserves for subsequent pregnancies. Some studies
reported a correlation between folate supplementation
and low homocysteine levels;14,26,27 however, other
studies failed to validate the correlation.12,28 In addition,
some studies reported that doses of 0.65–10 mg/day of
folic acid alone or together with vitamin B12 and B6
reduce fasting and post-methionine load levels by 25%–
50%, both in healthy subjects and hyperhomocysteinemia
and patients with vascular disorders.20 Usually, the total
folate intake of foods and supplements <200–250 g/day
correlates with hyperhomocysteinemia.20 The intake of
400 g/day in the second and third trimesters elevates
the concentration of red cell folate and umbilical cord
folate and prevents reduced serum folate and decreased
homocysteine concentrations in pregnancy.24 Reportedly,
higher doses were required to decline the maximal tHcy
in groups with impaired renal function or low folate
status.20 Furthermore, plasma homocysteine responded
to the folic acid supplementation at a dose of 500–600
g/day.29
Although the highest safe limit for the folate intake
remains unclear, it is typically considered up to 1
mg/day for adults; likewise, no consensus exists about
the highest safe concentration of blood folate. Serum
folate concentrations of >45 nmol/L are considered
supraphysiological.30 In fact, high folate levels have
been reported to disguise the symptoms of vitamin B12
deficiency.20,30 The homocysteine concentration is
determined by nutritional and genetic factors.30 Folate is
the most potent homocysteine predictor15,31 and serves
to provide the methyl group for the conversion of
homocysteine to methionine, which joins in proteins and
other crucial functions related methylation reactions.30
The most significant genetic predictor is the 677CT
on genes coding MTHFR. Reportedly, individuals with
polymorphic homozygotes decreased the MTHFR
activity, resulting in the increased homocysteine.15
Obwegeser et al. reported that hormonal factors affect
homocysteine levels during pregnancy.31 Concentrations
of tHcy during pregnancy are induced by hormones and
exert a stronger effect than vitamins in lowering
homocysteine concentrations.28 Cortisol and oestrogens
cause increased activity of the Hcy–methyltransferase
enzyme in the liver and methionine synthase in the
kidneys resulting in the increased remethylation from
Hcy to methionine.31 Studies in adult rats administered
with cortisol or oestradiol or a combination of both
reported a marked decline in plasma homocysteine
levels. An experiment concluded that cortisol was more
effective in decreasing plasma homocysteine than
oestradiol.31 Another study reported that tHcy concentrations were 29%–60% lower in pregnant women
than non-pregnant and reached the lowest levels in the
second trimester of pregnancy28 but increased slowly at
the end of the third trimester of pregnancy to attain the
August 2018 | Vol. 22 | No. 2
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similar concentration as non-pregnant women.26 Reportedly, increased homocysteine at the end of pregnancy is
a natural phenomenon that prepares the uterus for labour
by stimulating uterine cell contraction.26 Moreover, studies
on a term pregnancy in pigs reported a myo-metrium
spontaneous contraction after induced by homocysteine.32
In this study, we suspected a mild increment in
homocysteine levels to stimulate uterine contractions;
however, further research is warranted validate it.

Funding

In contrast to Wallace et al.,15 some previous studies15,21,27
that indicated a correlation between folic acid levels and
homocysteine in normal pregnancy. A lack of correlation
in this study was attributed to a mild increase in
homocysteine levels at term pregnancy. Although this
study determined mild hyperhomocys-teinemia in normal
pregnancy, it did not cause endothelial cell damage as
pre-eclampsia. Assumedly, higher levels of folate
(because of intake and supplementation) are observed in
normal pregnancy respondents so that high folate levels
could maintain endothelial cells. Furthermore, high
folate levels prevent free radicals that are formed by
auto-oxidation of homocysteine.24,25

1.

Limitations. This study has some limitation. First, this
study did not review the daily intake of folic acid and
protein before. Reportedly, a dietary history of high
folic acid increased serum/plasma levels of folate.27
Plasma or folate serum describes the folate intake in the
last few days. A study reported that the diet containing
excessive methionine increases homocysteine levels.33
Second, we also did not assess participants’ adherence
to folate supplementation during pregnancy and the
amount consumed. Folate supplementation increased
folate levels during labour.15 In this study, no folate and
homocysteine levels were known before pregnancy or in
the first trimester of pregnancy. Besides, blood sampling
was performed in a non-fasting state because of the
unlikely condition. Furthermore, the difference in the
gestational age in both study groups was so significant
that it affected the levels of folic acid and homocysteine.

Conclusions
This study reveals an insignificant negative correlation
between folic acid levels and homocysteine in preeclampsia, as well as in normal pregnancy. Hence,
further research is warranted in the MTHFR 677C and
larger studies that explore other potential causes.
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